Investors.lyratherapeutics.com

Lyra Therapeutics Reports First Quarter 2024 Financial Results and

WEB-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May --WATERTOWN, Mass., April 30, 2024 (GLOBE …

Actived: 6 days ago

URL: https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-reports-first-quarter-2024-financial-results

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 …

WEB-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 --WATERTOWN, Mass., March 21, 2024 …

Category: Health Go Health

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR …

WEBThe Phase 2 BEACON trial is a sham-controlled, parallel-group study to evaluate safety, tolerability, and pharmacokinetics of LYR-220 (7500µg MF) matrix, over a 24-week …

Category: Health Go Health

Lyra Therapeutics Announces Positive Topline Results for …

WEB7500 mcg dose of LYR-210 achieved statistically significant improvement in a composite of the 4 cardinal symptoms of CRS at weeks 16 (p=0.021), 20 (p=0.012) and 24 (p=0.016) …

Category: Health Go Health

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 …

WEB-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from …

Category: Health Go Health

SEC Filings Lyra Therapeutics, Inc.

WEBView HTML: Mar 22, 2024: Annual report which provides a comprehensive overview of the company for the past year. 10-K

Category: Health Go Health

Lyra Therapeutics Reports First Quarter 2023 Financial Results and

WEB-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 - …

Category: Health Go Health

Lyra Therapeutics to Report First Quarter 2021 Financial Results …

WEBWATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 27, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on …

Category: Health Go Health

Lyra Therapeutics Reports Topline Results from Phase 3 …

WEBTitle: Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhino sinusitis Created Date: 20240506120208Z

Category: Health Go Health

Lyra Therapeutics Reports First Quarter 2022 Financial Results and

WEBIn April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash …

Category: Health Go Health

Lyra Therapeutics Reports Second Quarter 2023 Financial Results …

WEB-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data …

Category: Health Go Health

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and

WEBSeptember 30, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 109,558 $ 45,747

Category: Health Go Health

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and

WEB– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological …

Category: Health Go Health